B. Riley has initiated coverage of Vanda Pharmaceuticals (VNDA) at buy saying that the company is currently trading at a valuation that is a "historic discount" and is "untenable." The firm has a ...
WASHINGTON, May 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VNDA) today announced financial and operational results for the first quarter ended March 31, 2025. "Vanda has entered a new growth ...
A series of increasing buyout offers has failed to convince Vanda's board of directors that the company should sell itself. After receiving "unsolicited" buyout proposals from Michigan-based CDMO ...
WASHINGTON, Jan. 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VNDA) today announced that it has received a decision letter from the U.S. Food and Drug Administration's (FDA) Center for Drug ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the initiation of Thetis, a clinical trial evaluating NEREUS™ (tradipitant) for the prevention of vomiting in patients receiving ...
Vanda Pharmaceuticals and AnaptysBio have announced a global license agreement for the development and commercialization of imsidolimab, an IL-36R antagonist that has completed two successful Phase 3 ...
Vanda Pharmaceuticals has agreed to a plan in which the Food and Drug Administration will conduct more reviews of two of its drugs to resolve disputes between the company and the agency. Under the ...
Vanda Pharmaceuticals, a company that develops medicines for conditions with limited to no treatment options, has signed a multi-year partnership with the New York Islanders to become their jersey ...
WASHINGTON, Jan. 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program. Gastroparesis is a serious digestive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results